Literature DB >> 21099223

The Glasgow Prognostic Score is a good predictor of treatment outcome in patients with unresectable pancreatic cancer.

Mitsugi Shimoda1, Masato Katoh, Junji Kita, Tokihiko Sawada, Keiichi Kubota.   

Abstract

BACKGROUND: We analyzed the outcome of patients with advanced unresectable pancreatic cancer treated in our department from 2001 to 2008.
METHODS: Of the 83 patients included in this study, 50 patients received single-agent treatment with gemcitabine (GEM), 9 patients GEM combined with radiotherapy (GEM+R) and 24 patients had best supportive care (BSC). We analyzed survival rates among the groups and risk factors for each group.
RESULTS: The 3-year survival rates were dismal: GEM group 2.9%, GEM+R group 0% and BSC group 0%. Significant prognostic factors of the study were: performance status (PS), response rate and decrease in the CA19-9 level. Significant prognostic factors by the Cox proportional hazard model were the albumin level prior to treatment, CA19-9 levels before treatment, decrease in CA19-9 and response rate. Albumin levels and the Glasgow Prognostic Score (GPS) were found to be factors affecting survival in the GEM group.
CONCLUSION: In this series of patients with unresectable pancreatic cancer, good PS, decrease in CA19-9 after treatment and good GPS determined prior to treatment were independent prognostic factors for better overall survival.
Copyright © 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21099223     DOI: 10.1159/000321014

Source DB:  PubMed          Journal:  Chemotherapy        ISSN: 0009-3157            Impact factor:   2.544


  24 in total

1.  The modified Glasgow Prognostic Score (mGPS) is a good predictor of indication for palliative bypass surgery in patients with unresectable pancreatic and biliary cancers.

Authors:  Yoshiaki Ikuta; Hiroshi Takamori; Yasuo Sakamoto; Daisuke Hashimoto; Akira Chikamoto; Hideyuki Kuroki; Kazuya Sakata; Keita Sakamoto; Hiromitsu Hayashi; Katsunori Imai; Hidetoshi Nitta; Masahiko Hirota; Keiichiro Kanemitsu; Toru Beppu; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2013-09-03       Impact factor: 3.402

2.  Ferritin as an independent mortality predictor in patients with pancreas cancer. Results of a pilot study.

Authors:  Marta Kalousová; Tomáš Krechler; Marie Jáchymová; Aleš A Kuběna; Aleš Zák; Tomáš Zima
Journal:  Tumour Biol       Date:  2012-08-10

3.  Evaluation of inflammation-based markers for predicting the prognosis of unresectable pancreatic ductal adenocarcinoma treated with chemotherapy.

Authors:  Hiroyuki Asama; Rei Suzuki; Tadayuki Takagi; Mitsuru Sugimoto; Naoki Konno; Ko Watanabe; Jun Nakamura; Hitomi Kikuchi; Mika Takasumi; Yuki Sato; Hiroki Irie; Takuto Hikichi; Hiromasa Ohira
Journal:  Mol Clin Oncol       Date:  2018-08-10

4.  Risk Factors for Early Recurrence of Single Lesion Hepatocellular Carcinoma After Curative Resection.

Authors:  Mitsugi Shimoda; Kazuma Tago; Takayuki Shiraki; Shozo Mori; Masato Kato; Taku Aoki; Keiichi Kubota
Journal:  World J Surg       Date:  2016-10       Impact factor: 3.352

5.  Glasgow Prognostic Score as a useful prognostic factor after hepatectomy for hepatocellular carcinoma.

Authors:  Kei Horino; Toru Beppu; Hideyuki Kuroki; Kosuke Mima; Hirohisa Okabe; Osamu Nakahara; Yoshiaki Ikuta; Akira Chikamoto; Takatoshi Ishiko; Hiroshi Takamori; Hideo Baba
Journal:  Int J Clin Oncol       Date:  2012-07-21       Impact factor: 3.402

6.  Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010.

Authors:  Sophie Cai; Theodore S Hong; Saveli I Goldberg; Carlos Fernandez-del Castillo; Sarah P Thayer; Cristina R Ferrone; David P Ryan; Lawrence S Blaszkowsky; Eunice L Kwak; Christopher G Willett; Keith D Lillemoe; Andrew L Warshaw; Jennifer Y Wo
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860

7.  Use of gemcitabine as a second-line treatment following chemotherapy with folfirinox for metastatic pancreatic adenocarcinoma.

Authors:  Matthieu Sarabi; Laetitia Mais; Nadia Oussaid; Françoise Desseigne; Pierre Guibert; Christelle De La Fouchardiere
Journal:  Oncol Lett       Date:  2017-04-20       Impact factor: 2.967

8.  Prognostic factors in patients with metastatic or recurrent pancreatic cancer treated with first-line nab-paclitaxel plus gemcitabine: implication of inflammation-based scores.

Authors:  Inhwan Hwang; Jihoon Kang; Hei Nga Natalie Ip; Jae Ho Jeong; Kyu-Pyo Kim; Heung-Moon Chang; Changhoon Yoo; Baek-Yeol Ryoo
Journal:  Invest New Drugs       Date:  2018-10-16       Impact factor: 3.850

9.  Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score.

Authors:  Sinziana Dumitra; Mohammad H Jamal; Jad Aboukhalil; Suhail A Doi; Prosanto Chaudhury; Mazen Hassanain; Peter P Metrakos; Jeffrey S Barkun
Journal:  HPB (Oxford)       Date:  2013-03-22       Impact factor: 3.647

10.  Prognostic value of the Memorial Sloan Kettering Prognostic Score in metastatic pancreatic adenocarcinoma.

Authors:  Justin M Lebenthal; Junting Zheng; Paul A Glare; Eileen M O'Reilly; Andrew C Yang; Andrew S Epstein
Journal:  Cancer       Date:  2021-01-20       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.